Actuate Therapeutics (ACTU) Competitors $8.28 -0.25 (-2.87%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. TRML, PRME, BCYC, ARVN, KURA, TBPH, SAGE, ORKA, RAPP, and SLDBShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Tourmaline Bio (TRML), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Arvinas (ARVN), Kura Oncology (KURA), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), Rapport Therapeutics (RAPP), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Tourmaline Bio Prime Medicine Bicycle Therapeutics Arvinas Kura Oncology Theravance Biopharma Sage Therapeutics Oruka Therapeutics Rapport Therapeutics Solid Biosciences Actuate Therapeutics (NASDAQ:ACTU) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Do analysts rate ACTU or TRML? Actuate Therapeutics currently has a consensus price target of $20.50, indicating a potential upside of 147.44%. Tourmaline Bio has a consensus price target of $50.14, indicating a potential upside of 130.65%. Given Actuate Therapeutics' higher probable upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, ACTU or TRML? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/ATourmaline BioN/AN/A-$73.21M-$3.21-6.77 Does the media prefer ACTU or TRML? In the previous week, Tourmaline Bio had 7 more articles in the media than Actuate Therapeutics. MarketBeat recorded 8 mentions for Tourmaline Bio and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.93 beat Tourmaline Bio's score of 0.89 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Actuate Therapeutics Positive Tourmaline Bio Positive Do insiders & institutionals believe in ACTU or TRML? 91.9% of Tourmaline Bio shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ACTU or TRML more profitable? Actuate Therapeutics' return on equity of 0.00% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -339.73% Tourmaline Bio N/A -26.75%-26.11% SummaryActuate Therapeutics beats Tourmaline Bio on 5 of the 9 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$169.60M$3.08B$5.57B$9.82BDividend YieldN/A2.27%4.62%4.12%P/E RatioN/A20.4630.1325.55Price / SalesN/A322.08447.00105.31Price / CashN/A42.0537.7558.93Price / Book828.507.568.395.97Net Income-$27.28M-$54.65M$3.25B$264.84M7 Day Performance2.66%4.43%3.47%2.27%1 Month Performance33.63%5.68%3.82%1.16%1 Year Performance-9.45%31.16%35.58%28.37% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.5929 of 5 stars$8.29-2.9%$20.50+147.4%-0.9%$169.60MN/A0.0010Gap UpTRMLTourmaline Bio2.5484 of 5 stars$22.12+2.5%$49.33+123.0%+55.0%$569.82MN/A-6.9144News CoverageEarnings ReportAnalyst ForecastPRMEPrime Medicine3.5426 of 5 stars$4.18-7.2%$9.25+121.6%-11.2%$566.50M$3.85M-2.05234Analyst RevisionGap DownBCYCBicycle Therapeutics3.4585 of 5 stars$8.15+1.2%$24.22+197.2%-67.2%$562.66M$35.28M-2.59240Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionARVNArvinas3.8968 of 5 stars$7.69+2.2%$20.29+163.7%-70.7%$560.56M$263.40M-11.64420Analyst RevisionKURAKura Oncology3.5417 of 5 stars$6.41+1.4%$24.50+282.5%-65.9%$559.33M$53.88M-3.08130News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTBPHTheravance Biopharma2.0598 of 5 stars$11.20-0.2%$16.60+48.3%+50.0%$558.50M$64.38M-9.47110News CoverageEarnings ReportSAGESage Therapeutics3.8804 of 5 stars$8.68flat$8.02-7.7%N/A$543.54M$41.24M-1.78690ORKAOruka Therapeutics2.987 of 5 stars$14.62+2.2%$40.38+176.2%N/A$542.32MN/A-3.21N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRAPPRapport Therapeutics1.7173 of 5 stars$14.88+5.9%$28.00+88.2%-23.4%$540.57MN/A-4.29N/AEarnings ReportAnalyst RevisionSLDBSolid Biosciences3.2696 of 5 stars$6.77-0.8%$15.10+123.1%-8.4%$528.39M$8.09M-2.28100News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies TRML Competitors PRME Competitors BCYC Competitors ARVN Competitors KURA Competitors TBPH Competitors SAGE Competitors ORKA Competitors RAPP Competitors SLDB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access